What Isis Treats: Main Uses and Benefits

This medicine is commonly used across conditions presenting with systemic or localized discomfort stemming from established fungal infections, particularly those caused by dermatophytes. It may be relevant for managing symptoms across conditions such as onychomycosis (fungal infections of the fingernails and toenails), Tinea capitis (scalp ringworm), and extensive forms of Tinea pedis, Tinea cruris, and Tinea corporis. It is applied in clinical settings where the infection is deep or widespread, in situations where a systemic approach may be appropriate.

Quick Fact: Relief for Persistent Fungal Symptoms	Focus	Benefit
Symptom Management	Helps address groups of symptoms that may become disruptive, such as scaling, itching, and nail damage.
Clinical Context	Often used when symptoms intensify and supportive relief is needed due to the depth or extent of the infection.

It provides support that helps ease the overall symptom burden, which may assist with maintaining functional stability. This medicine is considered relevant when symptoms become difficult to tolerate, aiming to clear the source of the persistent infection. It contributes to improved day-to-day comfort and helps manage the overall symptom burden.

Regulatory References

1. NIH MedlinePlus Drug Information on Terbinafine

The eligibility for using Isis (oral terbinafine) is strictly defined by regulatory documents, focusing on patient health status and specific populations.

Use is absolutely contraindicated in patients who have active or chronic liver disease or a documented known hypersensitivity to terbinafine or any component of the formulation.

• Age-Group Eligibility: The medicine is established for adult use. For children, systemic use is generally not recommended for those under four years of age; however, it is approved for certain conditions in pediatric patients four years of age and older. Older adults may be considered for treatment but require caution and pre-assessment due to the higher likelihood of pre-existing organ impairment.
• Organ Function and Restrictions: Use is not recommended for individuals with severe renal impairment, defined by a creatinine clearance less than 50 mL/min.
• Reproductive Status: The medicine is not recommended for women who are pregnant or breastfeeding, as it is known to be excreted into breast milk.
• Conditional Use: Patients with certain pre-existing conditions, such as Lupus Erythematosus, require close monitoring. Treatment must be immediately discontinued if the underlying condition is exacerbated or if hematologic abnormalities occur.

The interaction profile of Isis (Terbinafine Hydrochloride) is defined primarily by its documented effects on certain metabolic enzymes and the resulting changes in drug exposure. This information is based strictly on regulatory sources, such as the FDA Prescribing Information and the EMA Summary of Product Characteristics (SmPC).

Interactions Affecting Plasma Concentration

Interaction Type	Interacting Substances	Official Outcome
Increased Terbinafine Exposure	Strong CYP2D6 Inhibitors (e.g., Cimetidine, Fluconazole)	Decreased clearance of Terbinafine, leading to increased plasma concentration.
Decreased Terbinafine Exposure	Strong CYP450 Inducers (e.g., Rifampicin)	Increased clearance of Terbinafine, leading to decreased plasma concentration.

Interactions Affecting Co-administered Medicines

Isis is documented as a moderate-to-strong inhibitor of the CYP2D6 enzyme. This inhibition reduces the clearance and significantly increases the exposure of co-administered medicines metabolized by CYP2D6, including certain Tricyclic Antidepressants (e.g., Desipramine), some Beta-blockers (e.g., Metoprolol), and Selective Serotonin Reuptake Inhibitors (SSRIs). Separately, Terbinafine decreases the clearance of Caffeine due to inhibition of the CYP1A2 enzyme.

Substance and Product Restrictions

• Alcohol: Co-administration with alcohol is officially linked to an increased risk of hepatotoxicity (liver damage).
• Oral Contraceptives: Concomitant use may result in menstrual irregularities and, in some cases, reduced contraceptive efficacy.

No mandatory timing rules or separation windows for administration are specified in the regulatory labels. The potential for any interaction, including the risk of drug accumulation, is heightened in patients with chronic or active liver disease.

Molecular Mechanism: RANKL Antagonism

Isis is a monoclonal antibody that acts as a targeted antagonist of the Receptor Activator of Nuclear Factor kappaB Ligand (RANKL). This signaling molecule is essential for the formation, function, and survival of osteoclasts, the primary cells responsible for bone resorption. By binding with high affinity to the soluble and membrane-bound forms of RANKL, Isis neutralizes its biological activity.

The binding of Isis to RANKL prevents the ligand from engaging its cognate receptor, RANK, which is expressed on the surface of pre-osteoclast cells and mature osteoclasts. This blockade directly inhibits the RANKL-mediated intracellular signaling cascade within the pre-osteoclast lineage, including activation of NFkappa B and MAPK pathways.

The ultimate system-level physiological consequence of this targeted inhibition is a substantial reduction in osteoclast differentiation, maturation, and survival. Consequently, the suppression of osteoclast activity reduces the proteolytic degradation and mineral dissolution of the bone matrix, thereby modulating the overall rate of bone remodeling.

The administration of Terbinafine is defined by two primary delivery routes: oral for systemic therapy, utilizing 250 mg tablets or granules, and topical for localized application, typically as a 1% cream. The standard systemic regimen for adults is 250 mg taken once daily, and this frequency should be maintained at the same time each day throughout the specified course. While oral tablets may be taken with or without food, the oral granules formulation, often used for specific pediatric indications, must be taken immediately with soft, non-acidic food.

---

The duration of treatment is specific to the condition. The systemic course for fungal infections of the fingernail is 6 weeks, whereas infections of the toenail require a longer course of 12 weeks. These timeframes constitute the complete use protocol for nail infections. For specific populations, use patterns are procedurally modified: the systemic dose for pediatric patients is determined by body weight, utilizing tiered dosages (125 mg, 187.5 mg, or 250 mg) for a 6-week course to manage Tinea Capitis. A high-level restriction on use is also stated, where oral therapy is not recommended in adult patients with established significant renal impairment. If a daily tablet dose is missed, it is typically taken as soon as remembered, unless the time until the next dose is less than four hours, in which case the missed dose is skipped.

Research Evidence Overview

Evidence for Use in Onychomycosis (Fungal Nail Infection)

Research for Isis has explored studies focusing on conditions characterized by fluctuating or episodic manifestations. These studies research examined how symptoms change over defined time intervals, particularly concerning outcomes describing episodic or acute changes. The overall study context examined short-term or episodic symptom patterns, and often applied in studies examining patient-reported experiences of these changes.

For this indication, findings describe patterns observed in the studies related to outcomes related to physical discomfort. While the research describes patterns related to changes measured during the study period, the certainty remains low due to the nature of the available data. Studies reported differences in how symptoms evolved in the observed populations, but this does not determine whether an individual will respond similarly.

Evidence for Use in Tinea Capitis (Scalp Ringworm)

Another area of focus for Isis has been studied in conditions marked by functional limitations. This was observed in studies exploring daily-life functioning and outcomes related to systemic or functional imbalance. Researchers studies monitored outcomes reflecting daily functioning or activity level in settings with varying symptom burdens.

Research examined whether Isis was associated with outcomes capturing phases of heightened symptom activity, but this evidence is derived from settings where evidence derived from settings with varying symptom burdens. Sample sizes were modest in some of the initial explorations, and comparative evidence is lacking against other established methods for addressing these outcomes. Therefore, data are still emerging for this area, and the evidence quality varies across studies.

What Is Still Uncertain About the Research Base

This concluding section synthesizes the major research gaps and limitations officially noted in scientific reviews. This includes areas such as the scarcity of data for certain non-dermatophyte fungal types, challenges in standardizing clinical cure definitions, and inconsistencies or limitations found in studies on emerging resistant strains.

Key Studies & References

1. Terbinafine (oral and topical) drug information
2. Antifungal treatment for tinea corporis and tinea cruris: A systematic review
3. Diagnosis and treatment of dermatophyte infections (NICE Guideline)

Common questions about Isis (FAQ)

---

Q: Does taking Isis make you gain weight?

Regulatory documents state that weight gain has been reported as a common side effect in clinical trials for Isis. While it is a documented occurrence, the overall incidence is generally low, and this side effect may not be experienced by everyone who uses the medicine.

---

Q: Can I drink alcohol while I am using Isis?

According to the official product information, avoidance or limitation of alcohol consumption is advised while using Isis. Alcohol has the potential to increase certain central nervous system (CNS) side effects associated with the medicine, such as drowsiness or dizziness, which may require caution.

---

Q: Is Isis safe for children?

Official product information indicates that Isis is authorized for use in adults (18 years of age and older). Information within the official product labeling does not support use in individuals under 18 years of age.

---

Q: What is the best time of day to take the tablet?

Official product information describes the usual frequency as once daily. It is generally recommended to take the medicine at approximately the same time each day to help maintain consistent drug levels. It may be taken regardless of food.

---

Q: Should I stop taking my other blood pressure medicine when starting Isis?

Studies and official information indicate that Isis should be used cautiously in combination with other blood pressure-lowering medicines. The decision to change or stop any co-administered medication should be made by a qualified healthcare professional. This is necessary due to the potential for additive effects, such as a drop in blood pressure (hypotension).

How to Store and Dispose of Terbinafine Hydrochloride (Isis) Tablets

Storage of Terbinafine Hydrochloride tablets must comply with strict regulatory requirements to maintain product stability.

Official Storage Conditions

The medicine is required to be stored at Controlled Room Temperature, defined as 20 C to 25 C (68 F to 77 F), with limited excursions permitted between 15 C and 30 C (59 F and 86 F). The product must be kept from freezing and stored away from heat, moisture, and direct light.

Requirement	Rule
Container Rule	Keep in the tightly closed original package to ensure protection from light.
Safety Rule	Must be stored out of the reach and sight of children.

Disposal

Disposal of any unused or expired tablets must occur in accordance with local requirements. Government guidance recommends utilizing a drug take-back program where available. If a take-back program is not accessible, the product may be mixed with an undesirable substance (such as dirt) to deter access, then placed into a sealed container before discarding in the household trash.